Objective:We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain.Methods:The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish radiotherapy departments (RTDs) were collected.Results:A total of 1505 NSCLC-SIII patients from 35 RTDs from 2018 to 2021 were recruited. A total of 871 patients (57.9%) received concurrent chemoradiotherapy (cCRT), and 390 patients (25.91%) received maintenance durvalumab. The immunotherapy (IT) was well tolerated, with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0–2 toxicity observed in 85% of the patients (295 patients). The median overall survival (OS) was 26 months (95% CI 9.4-Not Reached NR). There was a statistically significant difference when patients were stratified by IT, with a median OS of 40 months (95% CI 22.1-NR) in the IT maintenance cohort compared with 19.4 months (95% CI 7.1–58.1) in the non-IT cohort. Differences were also noted in progression-free survival (PFS), with a median PFS of 20.8 months (95% CI 9.6-NR) in the IT cohort versus 8.4 months (95% CI 3.1–25.1) in the non-IT cohort. These differences remained significant according to the multivariate model (OS: HR 0.45 [95% CI 0.36–0.56],p< 0.001; PFS: HR 0.5 [95% CI 0.42–0.59],p< 0.001).Conclusions:The management of NSCLC-SIII patients can vary, leading to differences in treatment outcomes. The treatment of lung cancer in NSCLC-SIII patients in RTDs across Spain aligns with international guidelines and expert recommendations.
目的：本研究旨在为西班牙III期非小细胞肺癌（NSCLC-SIII）的临床管理提供真实世界数据。方法：GOECP-SEOR研究组开展了一项观察性、回顾性、多中心研究，收集了西班牙各放疗科收治的NSCLC-SIII患者的诊疗数据。结果：研究共纳入2018年至2021年间来自35个放疗中心的1505例NSCLC-SIII患者。其中871例患者（57.9%）接受了同步放化疗，390例患者（25.91%）接受了度伐利尤单抗维持治疗。免疫治疗耐受性良好，85%的患者（295例）仅出现0-2级不良事件通用术语标准毒性反应。中位总生存期为26个月（95% CI 9.4-未达到）。按是否接受免疫治疗分层分析显示，免疫治疗维持组中位总生存期达40个月（95% CI 22.1-未达到），显著优于非免疫治疗组的19.4个月（95% CI 7.1-58.1），差异具有统计学意义。无进展生存期同样存在显著差异：免疫治疗组中位无进展生存期为20.8个月（95% CI 9.6-未达到），而非免疫治疗组仅为8.4个月（95% CI 3.1-25.1）。多变量模型分析证实这些差异具有统计学显著性（总生存期：HR 0.45 [95% CI 0.36-0.56]，p<0.001；无进展生存期：HR 0.5 [95% CI 0.42-0.59]，p<0.001）。结论：NSCLC-SIII患者的临床管理方案存在差异，这可能导致治疗结果的不同。西班牙各放疗中心对NSCLC-SIII肺癌患者的治疗实践符合国际指南和专家共识。
Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR
肿瘤(癌症)患者之家